• Home
• Defective Drug Index
• About A Drug Recall
• Contact A Defective Drug Lawyer

We Can Help.

Primary Pulmonary Hypertension Injury

A Primary Pulmonary Hypertension injury is a rare, but fatal, heart valve condition that can be caused by taking defective diet drugs. Numerous Primary Pulmonary Hypertension injury cases have been linked to the use of diet drugs that were prescribed to six to seven million Americans. The drugs Pondimin (fenfluramine), Redux (dexfenfluramine), and Fen-Phen (the combination of fenfluramine and phentermine) were pulled off the market in 1997 after medical studies discovered an overwhelming number of Primary Pulmonary Hypertension injury cases among Fen Phen users.

Fen Phen drugs had been available on the US market since the 1970s and were widely prescribed in hospitals and weight loss centers. Before the recall, an estimated eighteen million prescriptions for Fen Phen were written by medical professionals across the world. The drug's maker's consistently maintained that their product was both safe and effective. Wyeth, a division of American Home Products Corporation, recalled these drugs after the FDA received reports that hundreds of Fen Phen users suffered a Primary Pulmonary Hypertension injury while taking Fen Phen.

Mayo Clinic research results were also responsible for prompting the recall of these dangerously defective drugs. The Mayo study evaluated the echocardiograms of patients who had taken Pondimin and Redux. An echocardiogram is a medical test that is performed to test the functioning of the heart valves. Approximately thirty percent of those studied had abnormal echocardiogram results, indicating a potential Primary Pulmonary Hypertension injury. Many of these patients were asymptomatic but tested positive for a Primary Pulmonary Hypertension injury or related condition. The Mayo Clinic also discovered 24 cases of Primary Pulmonary Hypertension injury in patients who had taken Fen-Phen.

A Primary Pulmonary Hypertension injury is a progressive and fatal condition for which there is no known cure. A Primary Pulmonary Hypertension injury causes a drastic and dangerous increase in the blood pressure of the pulmonary artery, which is responsible for pumping blood from the heart to the lungs. When a person suffers a Primary Pulmonary Hypertension injury, there is an increased resistance in blood flow thereby causing a build up of tissue in the artery walls and expansion of the heart and right ventricle. The diagnosis of a Primary Pulmonary Hypertension injury has an average prognosis of three years before complications from this condition prove deadly.

Symptoms of a Primary Pulmonary Hypertension injury can include: fatigue, trouble breathing, chest pain, dizziness, fainting spells, leg swelling, bluish skin and lips, racing pulse, heart palpitations, and heart murmurs. A Primary Pulmonary Hypertension injury case can be managed through surgery, prescription medications, supplemental oxygen, and the like.

If you or a loved one had taken Fen Phen and subsequently developed a Primary Pulmonary Hypertension injury, you may wish to contact a legal professional who can determine your legal rights and options. Please contact us to speak with a qualified and experienced Primary Pulmonary Hypertension injury attorney who can protect and maximize your legal interests.

More Fenphen Resources

Pulmonary Hypertension Resource - News, Information and Resources regarding Primary Pulmonary Hypertension and other forms of Severe Pulmonary Hypertension.

Pulmonary Hypertension Association - Features association background, disease and treatment information, news, research, and message boards.

• Reglan
• Raptiva
• Yaz Birth Control
• Nuvaring
• Duragesic Patch
• Heparin